Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters.

In patients with primary resectable breast cancer, a positive correlation between the age and the count of CD16+ lymphocytes and a negative correlation of this parameter with the number of regulatory CD4+CD25+CD127- cells and proliferative activity of Ki-67 tumor cells were revealed. Higher level of Ki-67 was associated with reduced number of effector lymphocytes (CD8+ and CD16+) and elevated content of regulatory CD8+CD11b-CD28- T cells. The absence of expression of estrogen receptors was associated with reduced cytotoxic potential of CD8+ T cell in comparison with ER+ breast cancer. The percentage of CD8+ lymphocytes (CD3+CD8+ and CD8+CD11b+CD28+) among lymphocytes infiltrating the tumor was higher in PR+ breast cancer than in PR- tumors. With increasing the tumor load, the number of lymphocytes expressing CD16 marker and their cytotoxic potential decreased.

Effect of Herbal Homeopathic Monopreparations on the Rate of Tissue Lymphatic Drainage in Healthy Mice.

We studied the effects of homeopathic monopreparations of plant origin Atropa Belladonna and Rhus toxicodendron in three dilutions (potencies) on interstitial humoral transport in healthy laboratory mice assessed by the rate of excretion of the lymphotropic label from the mesentery according to the Oyvin's method (vital biomicroscopy of intestinal mesentery in small animals). The homeopathic monopreparations exerted a dose-dependent inhibitory effect on the interstitial transport and lymphatic drainage in tissues of healthy mice.

[The role of epithelial antigens in diagnosis and staging of breast cancer]. / Rol' épitelial'nykh antigenov v diagnostike i stadirovanii raka molochnoi zhelezy.

The study of different epithelial antigen expression has been performed in 183 breast cancers. In 73 patients regional lymph nodes were studied as well. Panepithelial antigen Egp-34 (Mab HEA-125) was expressed in 100% of primary tumors and metastases. Antigen MUC-1 (Mab ICO-25) was identified in 93% of breast cancers. Monomorphic type of expression in tumor cells was typical for Egp-34, MUC-1 being in certain cases expressed as a proportion of cells. Additional immunohistochemical study of regional lymph nodes with Mab to Egp34 and MUC-1 provides a 10% increase in the rate of breast cancer metastases detection compared to histological examination alone. The carcinoembryonic antigen (CEA) was useful in identification of metastases only in CEA-positive breast cancers.

[Combination of taxotere and doxorubicin in chemotherapy of disseminated breast cancer]. / Kombinatsiia taksotera i doksorubitsina v khimioterapii disseminirovannogo raka molochnoi zhelezy.

Chemotherapy (taxotere + doxorubicin) was given to 46 patients with disseminated breast cancer: first line--27 (group A) and second line (including treatment after anthracycline-containing combinations and taxol--19) (group B). Average effectiveness in group A was 70.4% (10/27); group B--42.1% (8/19). The highest response was shown by metastases to the lung, liver, peripheral lymph nodes and primary tumors; least response--metastases to bones and soft tissues. Remission duration ranged 3-26 months. Median remission duration in group A was significantly longer than in group B (13.3 +/- 1.0 and 7.0 +/- 1.4 months, respectively) (p(0 < 05). Remission is still on in 11 patients (more than 26 months). Toxic poisoning was moderate: neutropenia stage III-IV was reported in 82/225 cycles (36.4%) lasting more than 7 days in 4/225 cycles (1.7%), febrile neutropenia stage 1-II--10/225 cycles (4.4%); stomatitis and diarrhea stage III-IV--1/225 cycles (0.44%). Treatment was suspended because of hypertension in one patient. No other side effects stage III-IV were registered.

[Combination therapy including mutamycin (mitomycin C) in the treatment of advanced colorectal and gastric cancer]. / Kombinatsii s mutamitsinom (mitomitsin C) v lechenii disseminirovannogo raka tolstoi kishki i zheludka.

The paper reports the data on treatment of 57 patients with disseminated gastric and colorectal carcinoma using a combination of mutamycin + 5-fluorouracil + leucovorin + cisplatin. Overall response was 26.3% including complete--7.01 and partial--19.29%. Mean duration of complete and partial remission was 10.88 +/- 5.65 and 5.18 +/- 0.82 months, respectively. Treatment as first-line chemotherapy was significantly more effective (36.1 and 9.5%). The regimens proved relatively low-toxic and therefore, can be recommended for out-patient application.

[Combination therapy of patients with locally advanced breast cancer]. / Kombinirovannoe lechenie mestnorasprostranennogo raka molochnoi zhelezy.

The investigation involved 30 patients with locally advanced breast cancer (T3-4N1-2M0). Combination therapy comprised two courses: carboplatin 300 mg/m2, i.v., dropwise, on day 1; doxorubicin 30 mg/m2, i.v., bolus-flow, on days 1 and 8; 5-fluorouracil 350 mg/m2, i.v., bolus-flow, on days 1 and 8, and irradiation of the breast and regional metastasis area (single target dose--2 Gy, total target dose--40 Gy). Overall clinical response was 96.7% (29/30), mammography-wise--83.3% (25/30). All patients were found operable and radical mastectomy was performed in 25. Therapeutic effect stage III-IV was histologically confirmed in 40% (25/30), stage I-II--60% (15/25). Median overall and recurrence-free survival was not reached within 36 months in 24/30, relapse-free survival was been reported in 16/24 (66.6%), tumor progression--8/24 (33.4%). Three-year; host-mastectomy recurrence-free survival--68.8 +/- 16.0%.

[Immunocyte subpopulations in histologic sections of breast tumors]. / Subpopuliatsii immunotsitov v gistologicheskikh srezakh raka molochnoi zhelezy.

A study of tumor infiltrating lymphocytes was carried out on cryostat sections of breast tumors in 27 patients using 24 monoclonal antibodies. Two types of infiltration--stromal and intraparenchymal--were identified. Certain correlations characteristic of subpopulation levels of immunocompetent cells identifiable by monoclonal antibody clusters CD8, CD22, CD38 and CD7; CD74 and CD4; CD11b and CD22, CD37 were established. The study also established a correlation between levels of immunocompetent cells infiltration (CD4+, CD7+, CD8+ and CD11b+) and tumor size and regional lymph node involvement.

[The expression of leukocytic and related antigens on the cells of human breast cancer cells]. / Ekspressiia leikotsitarnykh i rodstvennykh im antigenov na kletkakh raka molochnoi zhelezy cheloveka.

Certain expression regularities of different markers in human breast cancer cells are demonstrated. Monomorphic determinants of HLA class II antigen are detected only in case of HLA class I expression and cancer-embryonal antigen (CEA); the latter is combined with HLA class I and ICO-84 antigens at a significantly higher rate. The expression effect of CEA and HLA-DR on the metastatic spreading rate of regional lymph nodes is marked. A heterogeneity of the single tumour and in patients with malignant breast cancer is determined by the presence of the "leucocytic" antigens and CEA. In parallel studies monoclonal antibodies (MAB) HMFG-1 and a common epithelial antigen are assayed. The antigen interacting with MAB HEA-125 is characterized by the monomorphic expression.